Genmab can resume enrolment in US trials of zalutumumab in head and neck cancer
This article was originally published in Scrip
Executive Summary
Genmab can resume patient enrolment in two clinical trials in head and neck cancer with its experimental monoclonal antibody zalutumumab (HuMax-EGFr), one of its most advanced products in development, as the US FDA has lifted its partial clinical hold on the trials after receiving the requested additional safety information on the drug.